Glaucoma misconceptions common among patients

Article

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed.

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed, according to a report published in the January/February issue of Clinical & Experimental Ophthalmology.

Helen Danesh-Meyer and colleagues from Greenelane Clinical Centre, Auckland, the Southern Eye Specialists, Christchurch and the University of Auckland, New Zealand recruited 208 glaucoma patients, 100 newly diagnosed glaucoma patients and 100 controls. Each subject completed a validated self-administered true/false questionnaire assessing glaucoma knowledge.

Established glaucoma patients had marginally but significantly (p<0.05) greater glaucoma knowledge scores than new patients. Both groups scored significantly better than the control population. Significant misconceptions regarding glaucoma include: 80% of all participants thought that topical medications could not have systemic side-effects and 48% of established glaucoma patients believed that symptoms would warn them of disease progression. One-third of new patients considered blindness to be a common outcome of glaucoma.

Glaucoma patients are likely to harbour significant misconceptions about the disease. As such, the authors of this report believe that educational materials should be tailored to address this issue.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.